Consulting
Process Development
Analytical Services
GMP Manufacturing
Facility Design & Process EngineeringOptimising Cost of Goods (COG) is essential for ensuring the long-term commercial success of cell and gene therapies. Our expert and proprietary modelling helps you make strategic, cost-effective manufacturing decisions at every stage.
Consulting
Cost of Goods
Why Does Cost of Goods Matter?
Manufacturing decisions made early in development have a lasting impact on the commercial viability of cell and gene therapies. Without a clear understanding of the cost structure, companies risk inefficient production, pricing misalignment, and barriers to investment.
A comprehensive Cost of Goods (COGS) assessment provides the financial insight needed to develop therapies that are not only effective, but also economically sustainable. By identifying cost drivers and forecasting long-term expenses, a COGS strategy supports informed decision-making, strengthens pricing and reimbursement planning, and improves investor confidence.
Our Process
Budgeting & Financial Planning
Developing cell and gene therapies is capital-intensive, with significant costs across research, clinical trials, regulatory approvals, and GMP manufacturing. A robust COG assessment helps companies estimate expenses, allocate resources efficiently, and secure funding for long-term success.
Manufacturing Cost Optimisation
CGT production involves complex processes, specialised facilities, and skilled labour, making manufacturing costs a major consideration. A COG analysis identifies key cost drivers, highlighting opportunities for process optimisation, automation, and strategic outsourcing.
Pricing Strategy & Market Access
Understanding manufacturing costs is essential for setting competitive pricing and securing reimbursement. A detailed COG evaluation ensures that pricing strategies align with production costs, market potential, and expected reimbursement rates, improving market access.
Decision-Making in Product Development
Determining whether to in-source or outsource manufacturing, invest in new technologies, or refine processes is a major challenge. A clear COG analysis supports these critical business decisions, ensuring cost-effective long-term strategies.
Scalability & Production Planning
As therapies move from clinical to commercial production, costs change significantly. COG modelling provides insight into scaling challenges, helping companies plan efficient, cost-effective expansion while maintaining quality and compliance.
Quality Control & Compliance
Regulatory and quality control requirements can significantly impact manufacturing costs. A structured COG analysis provides visibility into these expenses, helping companies make informed decisions about in-house testing, compliance investments, and risk mitigation.
Risk Assessment & Supply Chain Planning
Supply chain vulnerabilities, process failures, and regulatory hurdles can drive up costs. A COG strategy identifies potential risks early, enabling companies to implement cost-effective solutions that prevent financial setbacks.
Build or Buy Decisions
A COG analysis helps companies evaluate whether to build their own manufacturing facilities, partner with a CDMO or adopt a hybrid approach. This data-driven approach justifies investment decisions, identifies critical manufacturing junctions and ensures alignment with long-term strategic goals.
Investor Confidence
Investors expect a clear understanding of a product’s cost structure before committing funding. A strong COG analysis demonstrates financial foresight, improving investor confidence and supporting fundraising efforts.
Our Approach
We build tailored COGS models that combine your internal data with independent analysis, creating a foundation for confident, strategic decisions. Whether you’re planning for clinical supply, scaling up, or evaluating investment scenarios, our models help you understand what drives cost — and how to manage it.
Our team brings over 20 years of experience in cell and gene therapy, spanning process development, manufacturing, and facility design. We use this insight to uncover hidden inefficiencies, assess build-versus-buy strategies, and create cost-optimised pathways to commercial readiness.
With our support, you’ll be better equipped to demonstrate financial viability, align internal stakeholders, and navigate critical manufacturing decisions with confidence.
Service Benefits
Data-Driven Cost Optimisation
Identify and rank cost drivers early, reducing financial inefficiencies.
Improved Investor Readiness
Provide clear, well-supported financial projections to secure funding.
Scalable Manufacturing Roadmap
Develop strategies that ensure efficient cost management at every growth stage.
Better Pricing & Market Access
Align cost structures with pricing strategies to enhance market positioning.
Stronger Risk Management
Gain insights to mitigate financial, supply chain, and regulatory risks.
Smarter Build-or-Buy Decisions
Evaluate whether to invest in in-house facilities, leverage CDMO partnerships or adopt a hybrid approach.
Key Deliverables
Plan for a Cost-Effective Future
A strong COG strategy ensures your therapy remains financially viable from development through to commercialisation. Whether you’re assessing manufacturing costs, refining pricing strategies, or preparing for investment, we can help. Speak with our experts to build a cost-effective, scalable manufacturing strategy for your therapy.
